Amgen
Compare Amgen…Large-cap biopharma. MariTide: antibody-peptide conjugate combining GLP-1 agonism with GIPR antagonism, monthly or less frequent dosing. Phase 3 readout expected late 2026.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AmgenLarge-cap biopharma. MariTide: antibody-peptide conjugate combining GLP-1 agonism with GIPR antagonism, monthly or less frequent dosing. Phase 3 readout expected late 2026.
Browse all official SEC filings including annual reports, quarterly updates, and material event disclosures.
SEC filings for this company are not available at the moment.